Assessment of outcome of Ovarian Cancer Treatment; Retrospective cohort study.

Background: When it comes to women with malignant gynecological tumor diagnosis, ovarian cancer (OC) is the most prevalent cause of death. Generally, it ranks as the fifth most common cause of mortality for females. Objectives: The present study aimed to study the epidemiological characteristics and treatment outcomes of OC cases in the Clinical Oncology and Nuclear Medicine Department at Zagazig University Hospitals. Methods: This retrospective cohort study targeted seven years from January 2015 to December 2021 and was conducted on 160 medical files of patients with OC from the Clinical Oncology and Nuclear Medicine Department, Zagazig University hospitals. The data of pathological and epidemiological characters and their outcomes were studied. Results: 66.9% of the studied patients had surgery upfront. The most frequent surgery types were TAH + BSO + Surgical staging (38.3%), TAH+BSO (29.4%), and Fertility-sparing surgery was reported in 7.9% of the cases. Regarding primary chemotherapy (95.6%) of patients had Primary chemotherapy as follows (2.5%) Neoadjuvant treatment only, (45%) Adjuvant only, (23.7%) had neoadjuvant and adjuvant, (4.4%) Definitive, and (20%) Palliative treatment. Regarding Hormonal treatment; (6.9%) of patients had Hormonal treatment as follows (1.9%) Adjuvant, (1.3%) Definitive, and (3.7%) salvage for Recurrence. There was a highly significant decrease in all Survival parameters (Local recurrence Free Survival, Regional recurrence Free Survival, Distant metastasis Free Survival, Disease-Free Survival, Progression Free Survival, and Overall survival) as regards an increase in age, Advanced disease & stage and ECOG PS 3, increase in Stage, and Epithelial tumors (p < 0.01 respectively). The mean survival time (MST) was significantly reduced in the advanced disease group compared to other clinical presentation groups. MST was significantly reduced in the ECOG-3 group compared to other ECOG PS groups. MST was significantly reduced in the distant metastasis group compared to other extension of disease groups. MST was significantly reduced in the stage IV group compared to other histopathology stage groups. MST was significantly reduced in the serious adverse effects group compared to the no serious adverse effects group. Conclusion: This study demonstrates that age as an important epidemiological factor, histopathological finding assessment, surgical status, radiological, location, grading, tumor morphology, treatment, outcome, recurrence of tumor, disease-free survival, and overall survival that was collected from patient archives in Clinical Oncology and nuclear medicine department in Zagazig University Hospitals. Therefore, this data can provide preliminary information for upcoming research. [ABSTRACT FROM AUTHOR]